Pharmaceutical Drug Delivery Market Report 2026

The pharmaceutical drug delivery market size has grown strongly in recent years. It will grow from $1.88 trillion in 2025 to $2.0 trillion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, advancements in pharmaceutical formulations, growth in hospital infrastructure, increasing geriatric population, adoption of oral and injectable drug delivery methods.

The pharmaceutical drug delivery market size is expected to see strong growth in the next few years. It will grow to $2.61 trillion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emergence of biologics and biosimilars, integration of digital monitoring devices, innovations in nanocarrier systems, growth in home care and remote treatments, increasing demand for patient-centric therapies. Major trends in the forecast period include targeted drug delivery systems, nanotechnology-based formulations, wearable drug delivery devices, personalized medicine solutions, minimally invasive delivery methods.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the pharmaceutical drug delivery market in the coming years. The prevalence of chronic diseases refers to the total number of individuals living with long-term health conditions within a population at a given time. Pharmaceutical drug delivery supports patients with chronic diseases by enabling targeted administration of medications to specific areas of the body for effective treatment. For example, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, approximately 41 million deaths occur globally each year due to non-communicable diseases (NCDs), accounting for 74% of all deaths. Of these, 17.9 million deaths are attributed to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2 million to diabetes. Consequently, the rising burden of chronic diseases is fueling the growth of the pharmaceutical drug delivery market.

Major companies operating in the pharmaceutical drug delivery market are pursuing strategic partnerships to identify new transport targets and carrier molecules that enhance drug delivery to the brain. Strategic partnerships involve collaborations in which organizations combine complementary capabilities and resources to achieve shared objectives and improved outcomes. For example, in September 2023, Cordance Medical, a US-based medical equipment manufacturing company, entered into a strategic partnership with EXACT Therapeutics to facilitate more effective drug delivery to the brain. This collaboration integrates Cordance Medical’s NeuroAccess platform, which enables non-surgical opening of the blood-brain barrier (BBB), with EXACT Therapeutics’ Acoustic Cluster Therapy (ACT) technology. The partnership is intended to advance treatments for brain-related conditions, including tumors and neurodegenerative diseases, by improving the ability of therapeutics to reach the brain. EXACT Therapeutics is a UK-based clinical-stage biopharmaceutical company.

In February 2024, AbbVie, Inc., a US-based biopharmaceutical company, acquired ImmunoGen, Inc. for approximately $10.1 billion. Through this acquisition, AbbVie seeks to enhance its oncology drug delivery capabilities by incorporating ImmunoGen’s proprietary antibody-drug conjugate (ADC) platform, which enables the targeted delivery of cytotoxic agents to cancer cells and broadens its portfolio of precision cancer therapies. ImmunoGen, Inc. is a US-based biopharmaceutical company that specializes in targeted drug delivery solutions using antibody-drug conjugates (ADCs).

Major companies operating in the pharmaceutical drug delivery market are 3M Company., AbbVie Inc., Amgen Inc., AstraZeneca plc, Bayer AG, Becton Dickinson And Company, C. H. Boehringer Sohn AG & Co. KG, Boston Scientific Corporation, Bristol-Myers Squibb Company, Consort Medical plc, Eli Lilly and Company, Emergent Biosolutions Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Kite Pharma Inc., Merck & Co Inc., Nemera France SAS, Novartis AG, Pfizer Inc, Sanofi S. A., SHL Medical AG, Teva Pharmaceuticals Industries Ltd., West Pharmaceutical Services Inc., Aerogen Pharma Limited, AptarGroup Inc., Biocon Ltd., Catalent Inc., Evonik Industries AG, Inovio Pharmaceuticals Inc., Mylan NV, Sensile Medical Inc., Ypsomed Holding AG.

North America was the largest region in the pharmaceutical drug delivery market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pharmaceutical drug delivery market by increasing the cost of imported raw materials, devices, and active pharmaceutical ingredients, thereby affecting production timelines and pricing. The oral, injectable, and ocular segments in regions like Asia-Pacific and Europe are particularly impacted due to their reliance on global supply chains. While tariffs pose challenges in cost management, they have also incentivized local manufacturing, encouraged domestic sourcing, and spurred innovation in cost-effective delivery solutions, which could strengthen regional market resilience.

The pharmaceutical drug delivery market research report is one of a series of new reports that provides pharmaceutical drug delivery market statistics, including pharmaceutical drug delivery industry global market size, regional shares, competitors with a pharmaceutical drug delivery market share, detailed pharmaceutical drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug delivery industry. This pharmaceutical drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical drug delivery refers to the method or process of administering a drug to humans or animals to produce a therapeutic effect. It involves a formulation or device designed to deliver a medicinal substance to its intended site of action while minimizing exposure to non-target cells, organs, or tissues.

The primary pharmaceutical drug delivery routes of administration include oral, ocular, pulmonary, nasal, injectable, topical, and other routes. The oral route involves administering a drug through the mouth and is the most widely used method due to its ease of use, sustained and controlled drug release, and suitability for solid dosage forms. Pharmaceutical drug delivery is applied across a range of conditions, including infectious diseases, cancer, cardiovascular disorders, diabetes, respiratory diseases, central nervous system disorders, autoimmune diseases, and other applications. The key end users include hospitals, home care settings, ambulatory surgical centers (ASCs)/clinics, and other end users.

The pharmaceutical drug delivery market includes revenues earned by entities by administering a pharmaceutical compound to achieve a therapeutic effect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.